OCUL

Ocular Therapeutix, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-05

Figures on this page computed 2026-11-08 12:40 UTC

Last close

7.14USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-05

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-05
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
-511.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
-417.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
0.12Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.27 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.75x

2.59x

2.58x

1.10x

0.95x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-05

Sales1.75x
Its own average over 10 years, 29.7M.
Profit2.59x
Its own average over 10 years, -102.8M.
Free cash flow2.58x
Its own average over 10 years, -83.9M.
Debt1.10x
Its own average over 6 years, 69.8M.
Price0.95x
Its own average over 11 years, 8. Market data, 2026-11-04

Profit is furthest from its own average, at 2.59 times.

Sales is 1.75 times its own 10-year average; Profit is 2.59 times its own 10-year average; Free cash flow is 2.58 times its own 10-year average; Debt is 1.10 times its own 6-year average; Price is 0.95 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-05

Sales against its own 10-year average1.75
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
The filing itself
Profit against its own 10-year average2.59
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
The filing itself
Free cash flow against its own 10-year average2.58
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
The filing itself
Debt against its own 6-year average1.10
Source
filed
Statement
income
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
The filing itself
Price against its own 11-year average0.95Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD